ctdna-ngs versus routine tissue testing in patients with advanced nsclc
Published 2 years ago • 82 plays • Length 2:00Download video MP4
Download video MP3
Similar videos
-
2:08
could ctdna replace routine tissue testing for genotyping nsclc?
-
1:49
ctdna ngs for treatment decision-making in nsclc
-
2:38
improving target identification in patients with advanced nsclc via up-front ctdna
-
3:06
the application of liquid biopsy ctdna analysis in nsclc
-
1:07
ctdna mrd detection in patients with nsclc
-
4:25
technical considerations for ctdna testing in nsclc
-
1:14
detecting ctdna in patients with nsclc receiving adagrasib
-
5:33
somatic genomic landscape of advanced-stage cancer patients from clinical ngs analysis of ctdna
-
7:57
balancing next generation sequencing in tissue biopsy and liquid biopsy in clinical practice
-
1:22
the identification of actionable mutations in lung cancer via ctdna
-
0:48
recommendations for reporting ngs results in nsclc
-
2:08
managing lung cancer in ild patients and implementing ctdna testing in the nhs
-
0:53
"how can ctdna improve detection and monitoring of my specific cancer?”
-
6:34
plx8394 in patients with advanced cancer: activity, safety and ctdna
-
1:36
ctdna assay for detection of recurrent disease in patients with early-stage breast cancer
-
5:32
ctdna abnormalities in prostate cancer: distinctions in aa versus ca patients
-
46:19
the use of ctdna for molecular residual disease assessment and immunotherapy monitoring in nsclc
-
2:37
next-generation sequencing in patients with nsclc
-
0:42
ngs vs pcr for egfr genotyping in nsclc